Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sottostudio 03B: Uno studio sulle terapie immunitarie e combinate mirate nei partecipanti con carcinoma a cellule renali di seconda linea Plus (2L+) (MK-3475-03B)

23 settembre 2026 aggiornato da: Merck Sharp & Dohme LLC

Uno studio di fase 1b/2 sulle terapie immunitarie e combinate mirate nei partecipanti con RCC (U03): sottostudio 03B

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).

The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second line plus (2L+) clear cell renal cell carcinoma (ccRCC).

This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

263

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New South Wales
      • Blacktown, New South Wales, Australia, 2148
        • Blacktown Hospital ( Site 3601)
      • Kogarah, New South Wales, Australia, 2217
        • St George Hospital ( Site 3602)
    • Queensland
      • Herston, Queensland, Australia, 4029
        • Royal Brisbane and Women's Hospital ( Site 3603)
    • Victoria
      • Melbourne, Victoria, Australia, 3084
        • Austin Health ( Site 3600)
    • Ontario
      • Toronto, Ontario, Canada, M5G 1Z5
        • Princess Margaret Cancer Centre ( Site 3101)
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Jewish General Hospital ( Site 3100)
    • Araucania
      • Temuco, Araucania, Chile, 4800827
        • James Lind Centro de Investigacion del Cancer ( Site 4108)
      • Temuco, Araucania, Chile, 4810148
        • CIDO SpA-Oncology ( Site 4106)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 7500921
        • FALP-UIDO ( Site 4100)
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill-Clinical Area ( Site 4101)
    • Valparaiso
      • Viña del Mar, Valparaiso, Chile, 2520598
        • ONCOCENTRO APYS-ACEREY ( Site 4103)
      • Seoul, Corea del Sud, 03722
        • Severance Hospital ( Site 3802)
      • Seoul, Corea del Sud, 06351
        • Samsung Medical Center ( Site 3801)
    • Seoul
      • Songpagu, Seoul, Corea del Sud, 05505
        • Asan Medical Center ( Site 3800)
    • Ain
      • Vandœuvre-lès-Nancy, Ain, Francia, 54519
        • Institut De Cancerologie De Lorraine ( Site 3204)
    • Alsace
      • Strasbourg, Alsace, Francia, 67200
        • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 3203)
    • Haute-Garonne
      • Toulouse, Haute-Garonne, Francia, 31059
        • Institut Claudius Regaud ( Site 3200)
    • Île-de-France Region
      • Villejuif, Île-de-France Region, Francia, 94800
        • Gustave Roussy ( Site 3202)
      • Haifa, Israele, 3109601
        • Rambam Health Care Campus-Oncology Division ( Site 3500)
      • Jerusalem, Israele, 9112001
        • Hadassah Medical Center-Oncology ( Site 3504)
      • Petah Tikva, Israele, 4941492
        • Rabin Medical Center ( Site 3502)
      • Ramat Gan, Israele, 52621
        • Sheba Medical Center - Oncology Division ( Site 3501)
      • Tel Aviv, Israele, 6423906
        • Sourasky Medical Center ( Site 3503)
      • Auckland, Nuova Zelanda, 1023
        • Auckland City Hospital ( Site 3700)
    • North Holland
      • Amsterdam, North Holland, Olanda, 1066 CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 4402)
    • South Holland
      • Rotterdam, South Holland, Olanda, 3015 GD
        • Erasmus Medisch Centrum ( Site 4401)
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-796
        • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 4201)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4200)
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polonia, 80-952
        • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 4202)
      • Manchester, Regno Unito, M20 4BX
        • The Christie NHS Foundation Trust ( Site 3400)
    • England
      • Southampton, England, Regno Unito, SO16 6YD
        • Southampton General Hospital ( Site 3403)
    • Glasgow City
      • Glasgow, Glasgow City, Regno Unito, G12 0YN
        • The Beatson West of Scotland Cancer Centre ( Site 3405)
    • Lancashire
      • Preston, Lancashire, Regno Unito, PR2 9HT
        • Royal Preston Hospital ( Site 3406)
    • Leicestershire
      • Leicester, Leicestershire, Regno Unito, LE1 5WW
        • Leicester Royal Infirmary ( Site 3408)
    • London, City of
      • London, London, City of, Regno Unito, EC1A 7BE
        • Barts Health NHS Trust ( Site 3401)
    • Midlothian
      • Edinburgh, Midlothian, Regno Unito, EH4 2XU
        • Western General Hospital ( Site 3402)
    • Wales
      • Cardiff, Wales, Regno Unito, CF14 2TL
        • Velindre Cancer Centre Hospital ( Site 3407)
      • Madrid, Spagna, 28034
        • Hospital Universitario Ramon y Cajal ( Site 3301)
    • Catalonia
      • Barcelona, Catalonia, Spagna, 08035
        • Hospital Universitari Vall d Hebron ( Site 3300)
    • California
      • San Francisco, California, Stati Uniti, 94158
        • University of California at San Francisco ( Site 3008)
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06510
        • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011)
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • University of Chicago ( Site 3013)
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • University of Iowa ( Site 3012)
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48202
        • Henry Ford Health System ( Site 3014)
    • New York
      • New York, New York, Stati Uniti, 10016
        • Laura and Isaac Perlmutter Cancer Center ( Site 3016)
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center ( Site 3002)
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Duke Cancer Institute ( Site 3015)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • UPMC Cancer Center/Hillman Cancer Center ( Site 3017)
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Vanderbilt University Medical Center ( Site 3004)
    • Texas
      • Dallas, Texas, Stati Uniti, 75390
        • UTSW Medical Center ( Site 3003)
    • Pest County
      • Budapest, Pest County, Ungheria, 1122
        • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 4301)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Has a histologically confirmed diagnosis of locally advanced/metastatic clear cell renal cell carcinoma (ccRCC)
  • Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a programmed cell death ligand 1 (PD-(L)1) checkpoint inhibitor (in sequence or in combination with a vascular endothelial growth factor. - tyrosine kinase inhibitor [VEGF-TKI]) where PD-(L)1 checkpoint inhibitor treatment progression is defined by meeting ALL of the following criteria: (a) has received ≥2 doses of an anti-PD-(L)1 monoclonal antibody (mAb) (b) has shown radiographic disease progression during or after an anti-PD-(L)1 mAb as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by investigator (c) disease progression has been documented within 12 weeks from the last dose of an anti-PD-(L)1 mAb
  • Has experienced disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with a VEGF-TKI (in sequence or in combination with a PD-[L]1 checkpoint inhibitor) where VEGF-TKI treatment progression is defined by meeting the following criterion: has shown radiographic disease progression during or after a treatment with a VEGF-TKI as defined by RECIST 1.1 by investigator.
  • Is able to swallow oral medication
  • Has adequate organ function
  • Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks before randomization/allocation
  • Has resolution of toxic effects of prior therapy to ≤Grade 1
  • Has adequately controlled blood pressure (BP ≤150/90 mm Hg) with no change in hypertensive medications within 1 week before randomization/allocation
  • Male participants are abstinent from heterosexual intercourse or agree to use contraception during treatment with and for at least 7 days after the last dose of lenvatinib and /or belzutifan; 7 days after lenvatinib and/or belzutifan is stopped, if the participant is only receiving pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, MK-4830 or a combination of the aforementioned drugs, no contraception is needed
  • Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, MK-4830 or 30 days after the last dose of lenvatinib or belzutifan, whichever occurs last and must abstain from breastfeeding during the study intervention period and for at least 120 days after study intervention

Exclusion Criteria:

  • Has urine protein ≥1 g/24 hours and has any of the following: (a) a pulse oximeter reading <92% at rest, or (b) requires intermittent supplemental oxygen, or (c) requires chronic supplemental oxygen (d) active hemoptysis within 3 weeks prior to the first dose of study intervention
  • Has clinically significant cardiovascular disease within 12 months from the first dose of study intervention administration
  • Has had major surgery within 3 weeks before first dose of study interventions
  • Has a history of lung disease
  • Has a history of inflammatory bowel disease
  • Has preexisting gastrointestinal (GI) or non-GI fistula
  • Has malabsorption due to prior GI surgery or disease
  • Has previously received treatment with a combination of pembrolizumab plus lenvatinib
  • Has received prior treatment with belzutifan
  • Has received prior radiotherapy within 2 weeks of start of study intervention
  • Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention; killed vaccines are allowed
  • Has received more than 4 previous systemic anticancer treatment regimens
  • Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
  • Has an active infection requiring systemic therapy
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has a known history of Hepatitis B
  • Has had an allogenic tissue/solid organ transplant

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Coformulation Pembrolizumab/Quavonlimab

Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg). Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years).

Administered via IV infusion at a dose of 400 mg/25 mg Q6W

Altri nomi:
  • MK-1308A
Sperimentale: Coformulation Favezelimab/Pembrolizumab

Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg). Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).

Administered via IV infusion at a dose of 800 mg/200 mg Q3W

Altri nomi:
  • MK-4280A
Sperimentale: Pembrolizumab + MK-4830

Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to ~2 years).

Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

Altri nomi:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion at a dose of 800 mg Q3W

Sperimentale: Pembrolizumab + Belzutifan

Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Belzutifan will be administered orally once-daily (QD) until progressive disease or discontinuation.

Administered via oral tablet at a dose of 120 mg QD

Altri nomi:
  • MK-6482
  • WELIREG™

Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

Altri nomi:
  • MK-3475
  • KEYTRUDA®
Sperimentale: Belzutifan + Lenvatinib

Participants will receive Belzutifan 120 mg PLUS lenvatinib 20 mg. Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.

Administered via oral capsule at a dose of 20 mg QD

Altri nomi:
  • E7080
  • MK-7902
  • LENVIMA®

Administered via oral tablet at a dose of 120 mg QD

Altri nomi:
  • MK-6482
  • WELIREG™
Sperimentale: Pembrolizumab + Lenvatinib

Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.

Administered via oral capsule at a dose of 20 mg QD

Altri nomi:
  • E7080
  • MK-7902
  • LENVIMA®

Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

Altri nomi:
  • MK-3475
  • KEYTRUDA®

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
Lasso di tempo: Up to ~21 days

DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting >7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for >1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for >14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the safety lead-in phase will be presented.

Up to ~21 days
Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)
Lasso di tempo: Up to ~21 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the safety lead-in phase will be presented.

Up to ~21 days
Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE
Lasso di tempo: Up to ~21 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the safety lead-in phase will be presented.

Up to ~21 days
Efficacy Phase: Number of participants who experienced DLTs
Lasso di tempo: Up to ~21 days

DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting >7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for >1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for >14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the efficacy phase will be presented.

Up to ~21 days
Efficacy Phase: Number of participants who experience one or more AEs
Lasso di tempo: Up to ~56 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the efficacy phase will be presented.

Up to ~56 months
Efficacy Phase: Number of participants who discontinue study treatment due to an AE
Lasso di tempo: Up to ~56 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the efficacy phase will be presented.

Up to ~56 months
Efficacy Phase: Objective response rate (ORR)
Lasso di tempo: Up to ~56 months

ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Up to ~56 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Efficacy Phase: Duration of response (DOR)
Lasso di tempo: Up to ~56 months

For participants in the analysis population who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented evidence of CR or PR until progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1.

Up to ~56 months
Efficacy Phase: Progression-free survival (PFS)
Lasso di tempo: Up to ~56 months

PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 by BICR.

Up to ~56 months
Efficacy Phase: Overall survival (OS)
Lasso di tempo: Up to ~56 months

OS is defined as the time from randomization to death due to any cause.

Up to ~56 months
Efficacy Phase: Clinical benefit rate (CBR)
Lasso di tempo: Up to ~56 months

CBR is defined as the percentage of participants who have achieved CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease) of ≥6 months. Responses are according to RECIST 1.1 by BICR.

Up to ~56 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 dicembre 2020

Completamento primario (Effettivo)

23 luglio 2026

Completamento dello studio (Effettivo)

23 luglio 2026

Date di iscrizione allo studio

Primo inviato

10 novembre 2020

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2020

Primo Inserito (Effettivo)

12 novembre 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 3475-03B
  • MK-3475-03B (Altro identificatore: MSD)
  • 2019-003610-13 (Numero EudraCT)
  • KEYMAKER-U03 (Altro identificatore: MSD)
  • U1111-1294-4557 (Identificatore di registro: UTN)
  • 2023-506839-15-00 (Identificatore di registro: EU CT)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 2019 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi